Expert Interview
A Second Look: Speaking with a Nephrologist about Cabaletta Bio's candidate, CABA-201, a CD19-CAR T cell therapy in development for patients with lupus nephritis
Ticker(s): CABAInstitution: Stormont-Vail Health
- Nephrologist who sees 400 end stage renal disease patients, 150 which are on dialysis
- Division director of Nephrology and Stormont-Vail Health
- Medical director DaVita, University of Kansas Topeka Campus
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
